share_log

拜耳20亿美元收购美国生物制药商Vividion

Bayer buys US biopharmaceutical company Vividion for $2 billion

新浪財經 ·  Aug 5, 2021 02:06

Bayer, GermanyThe group announced on Thursday that it would buy US biopharmaceutical company Vividion Therapeutics for up to $2 billion to strengthen its ability to discover new treatments and increase the value of its drug pipeline.

The deal is expected to close in the third quarter. Bayer will pay $1.5 billion first and up to $500m when Vividion's business reaches certain milestones in the future.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment